Clinical trials: Early Parkinson's Disease
Early-onset Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment.
- Trial name
- NCT06608355
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Early Onset Parkinson Disease, Early Stage Parkinson Disease
Dual-task Performance in Young-onset PD
This study aimed to investigate the effects of Game based dual-task training with treadmill on executive function and dual-task performance in individuals with early-onset PD and discuss the correlation between the change values…
- Trial name
- NCT04033393
- Testing
- Game based dual-task training, Treadmill training
- Volunteers
- 40 people
- Sponsor
- National Yang Ming Chiao Tung University
Parkinson Disease
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
- Trial name
- NCT00148486
- Testing
- NS 2330
- Where
- 55 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
- Trial name
- NCT00076492
- Testing
- CoQ10, GPI 1485
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Rochester
Parkinson's Disease
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS).
- Trial name
- CONFIDENT-PD (NCT01060878)
- Testing
- PYM50028
- Where
- 111 sites in United States, Canada and 8 more
- Volunteers
- 425 people
- Sponsor
- Phytopharm
Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and…
- Conditions
- Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia, Non Pharmacological Intervention
- Trial name
- MUSENGAGE (NCT06688968)
- Testing
- neuropsychologist interview, questionnaire
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Parkinson Disease (PD), Gut Microbiota
Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease (PD) - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage PD Patients
Preclinical human trials will be utilized to validate the research direction, followed by clinical trials to assess the impact of a cocktail formula product containing the optimal probiotic Y7 combined metabolites on motor…
- Conditions
- Parkinson Disease (PD), Gut Microbiota, Probiotic
- Trial name
- NCT07619560
- Testing
- Y7
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Medical University
Parkinson's Disease (PD)
Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients
Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe…
- Trial name
- NCT06975059
- Testing
- NUSHU shoe
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Oxidative Stress is an Important Cause of Parkinson's Disease
Idebenone Treatment of Early Parkinson's Diseasesymptoms
On May 30,2018 ,Investigators intend to conduct a multicenter, randomized, double-blind, placebo-controlled study of idebenone in the treatment of early-stage Parkinson's disease with motor and non-motor symptoms which is to…
- Trial name
- ITEP (NCT03727295)
- Volunteers
- 180 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Parkinson Disease
Education for Adapted Physical Activity in Parkinson's Disease
Parkinson's disease is a progressive disorders characterized by motor and non-motor symptoms. Actual medical treatments are symptomatic and have little efficacy on late stage axial motor symptoms.
- Trial name
- ACTIF-PARK (NCT04340492)
- Testing
- Education to Adapted Physical Activity, Standard care
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Lille
Parkinson Disease
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- NCT04995081
- Testing
- Biological/Vaccine: Allogeneic HB-adMSCs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hope Biosciences Research Foundation
Parkinson's Disease
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
- Trial name
- NCT00407212
- Testing
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 301 people
- Sponsor
- Novartis
Parkinson Disease, Parkinsonian Syndrome
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks.
- Trial name
- NCT00096720
- Testing
- levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson Disease
Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease
Pre-Active PD is a randomized controlled feasibility study to evaluate the implementation of a telehealth-delivered physical activity behavior change intervention for people with early-mid stage Parkinson's disease.
- Trial name
- NCT05308238
- Testing
- Occupational therapy intervention group, Disease management education group
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- San Jose State University
Idiopathic Parkinson's Disease
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous clinical trial indicated that initial…
- Trial name
- NCT01470859
- Testing
- pramipexole, Sinemet CR
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huashan Hospital
Parkinson's Disease
Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist
The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.
- Trial name
- NCT01338662
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
Parkinson Disease, Neurodegenerative Diseases
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease.
- Trial name
- AFF011 (NCT02267434)
- Testing
- Low dose AFFITOPE® PD03A + Adjuvant, High dose AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in Austria
- Volunteers
- 36 people
- Sponsor
- Affiris AG